Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus’ orthobiologic products are now available in six countries in the Asia Pacific region.
Source: Bioventus LLC
In 1Q14, Bioventus acquired ex-U.S. DUROLANE assets from Galderma, which still manufactures the product.
Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus' orthobiologic products are now available in six countries in the Asia Pacific region.
Source:...
Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.
Bioventus’ orthobiologic products are now available in six countries in the Asia Pacific region.
Source: Bioventus LLC
In 1Q14, Bioventus acquired ex-U.S. DUROLANE assets from Galderma, which still manufactures the product.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.